Pharmacological Profile and Mechanism of Action
In modern pharmacology, aripiprazole is considered a prototype of agents that exert a stabilizing effect on the brain's dopaminergic systems. Unlike classical agents, it acts as a partial agonist at $D_2$ receptors with high binding affinity.
Its stabilizing effect is mediated through combined action on two key targets:
- presynaptic receptors (autoreceptors);
- postsynaptic $D_2$ receptors.
Extended Receptor Profile
In addition to its effects on the dopamine system, the drug's pharmacodynamics involve serotonin receptors. Aripiprazole exhibits the following properties regarding serotonin receptors:
- It is a partial agonist at $5-HT_{1A}$ and $5-HT_{2C}$ receptors.
- It acts as an antagonist at $5-HT_{2A}$ receptors.
This complex profile allows the medication to be successfully used in clinical practice for the treatment of severe psychiatric disorders.
Clinical Use and Safety
The proven efficacy of the drug is supported by randomized controlled trials (RCTs). Aripiprazole is commonly prescribed for:
- schizophrenia;
- schizoaffective disorder.
The main clinical advantage of this therapy is that the drug practically does not cause extrapyramidal symptoms, setting it favorably apart from many other neuroleptics.